Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology, according to the company’s website (see here: www.Amarantus.com). SNNLive caught up with Gerald Commissiong, President and CEO of Amarantus BioScience Holdings, Inc. at the LD Micro Invitational 2015 in Bel Air, CA.
Mr. Commissiong begins with an overview of Amarantus BioScience Holdings, and continues with an update since we last spoke with him in December 2014 (See here: Amarantus BioScience Holdings – Discusses Blood Test for Alzheimer’s and Updates on Clinical Programs for Degenerative Disorders). He goes on to discuss his insights for the rest of 2015 and goals for the Company in 2016. Since speaking with Mr. Commissiong, the Company has made the following announcements:
For more information about Amarantus BioScience Holdings, Inc., go to: www.Amarantus.com
© 2017 Stock News Now
Supported by Superior Web Solutions